Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Peter Mohr"'
Autor:
Inês Pires da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John J. Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L. Smith, Richard A. Scolyer, Ana M. Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne N. Lo, Alexander M. Menzies
Publikováno v:
Pires da Silva, I, Ahmed, T, McQuade, J L, Nebhan, C A, Park, J J, Versluis, J M, Serra-Bellver, P, Khan, Y, Slattery, T, Oberoi, H K, Ugurel, S, Haydu, L E, Herbst, R, Utikal, J, Pföhler, C, Terheyden, P, Weichenthal, M, Gutzmer, R, Mohr, P, Rai, R, Smith, J L, Scolyer, R A, Arance, A M, Pickering, L, Larkin, J, Lorigan, P, Blank, C U, Schadendorf, D, Davies, M A, Carlino, M S, Johnson, D B, Long, G V, Lo, S N & Menzies, A M 2022, ' Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 10, pp. 1068-1080 . https://doi.org/10.1200/JCO.21.01701
PURPOSE Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival to anti-programmed cell death protein 1 (anti–PD-1) monothera
Autor:
Muhammad Adnan Khattak, Jason J. Luke, Georgina V. Long, Paolo Antonio Ascierto, Piotr Rutkowski, Dirk Schadendorf, Caroline Robert, Jean-Jacques Grob, Luis de la Cruz Merino, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion -Sileni, Matteo S. Carlino, Peter Mohr, Ruixuan Jiang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M. Eggermont, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 40:9581-9581
9581 Background: Adjuvant pembro improved RFS vs placebo (HR, 0.61; 95% CI, 0.45-0.82) and had manageable safety in patients (pts) with resected high-risk stage II melanoma at second interim analysis of KEYNOTE-716 (NCT03553836). HRQoL results are pr
Autor:
Ralf Gutzmer, Maurizio Podda, Carmen Loquai, Reinhard Dummer, Thomas Haalck, Josef Koller, Michael Weichenthal, Wolfgang Tilgen, Daniela Göppner, Axel Hauschild, Dirk Schadendorf, Norbert H. Brockmeyer, Uwe Trefzer, Annette Stein, Helen Gogas, Peter Mohr, Erhard Hölzle, Lars Alexander Schneider, Cord Sunderkötter, Alexander Enk, Cornelia Mauch
Publikováno v:
Journal of Clinical Oncology. 33:4077-4084
Purpose To evaluate the efficacy, safety, tolerability, and quality of life (QoL) in patients receiving intravenous, intermittent high-dose interferon alfa-2b (IFN-α-2b [iHDI]) compared with standard high-dose IFN-α-2b (HDI). Patient and Methods Pa
Autor:
Jeffrey E. Gershenwald, Merrick I. Ross, Nageatte Ibrahim, Charles H. Yoon, Vernon K. Sondak, Jean-Jacques Grob, Piotr Rutkowski, John M. Kirkwood, Alexander M.M. Eggermont, Andrew Poklepovic, Jason J. Luke, Richard A. Scolyer, Georgina V. Long, Sama Ahsan, Peter Mohr, James R. Anderson, Matteo S. Carlino, Caroline Robert, Axel Hauschild, Paolo A. Ascierto
Publikováno v:
Journal of Clinical Oncology. 37:TPS9596-TPS9596
TPS9596 Background: Adjuvant pembrolizumab showed significantly longer recurrence-free survival than placebo in patients with resected stage III melanoma in the KEYNOTE-054 study. KEYNOTE-716 (NCT03553836) is a randomized, placebo-controlled, double-
Autor:
Michael Weichenthal, Peter Mohr, Claudia Pföhler, Dirk Schadendorf, Friedegund Meier, Jochen Utikal, Sebastian Haferkamp, Ingrid Feldmann-Böddeker, Alexander Kreuter, Julia Welzel, Jens Ulrich, Ralf Gutzmer, Selma Ugurel, Imke Satzger, Patrick Terheyden, Ulrike Leiter, Rudolf A. Herbst, Katharina C. Kähler
Publikováno v:
Journal of Clinical Oncology. 37:9505-9505
9505 Background: In melanoma, potential benefits of therapies after PD-1 inhibitor failure, including those BRAF positive patients who have already received combined BRAF-/MEK inhibitors before anti PD-1 are poorly defined. We therefore analyzed the
Autor:
Jean-Jacques Grob, Peter Mohr, Andrew Poklepovic, Richard A. Scolyer, Jason J. Luke, Vernon K. Sondak, Jeffrey E. Gershenwald, James R. Anderson, Matteo S. Carlino, Caroline Robert, John M. Kirkwood, Nageatte Ibrahim, Charles H. Yoon, Georgina V. Long, Alexander M.M. Eggermont, Sama Ahsan, Axel Hauschild, Paolo A. Ascierto, Merrick I. Ross
Publikováno v:
Journal of Clinical Oncology. 37:TPS145-TPS145
TPS145 Background: Adjuvant pembrolizumab showed significantly longer recurrence-free survival compared with placebo in resected stage III melanoma in the KEYNOTE-054 study [1]. KEYNOTE-716 is a randomized, placebo-controlled, multicenter phase 3 stu
Autor:
Ralf Gutzmer, Katharina C. Kähler, Felix Kiecker, Claudia Lorenz-Schlüter, Jessica C. Hassel, Christian Menzer, Dirk Schadendorf, Martin Kaatz, Thomas Eigentler, Lisa Zimmer, Christiane Windemuth-Kieselbach, Carola Berking, Friedegund Meier, Selma Ugurel, Peter Mohr, Jürgen C. Becker
Publikováno v:
Journal of Clinical Oncology. 36:9527-9527
9527Background: Merkel cell carcinoma (MCC) is a rare, immunogenic, and highly aggressive skin cancer. Almost 40% of patients with completely resected MCC will relapse within the first two years af...
Autor:
D. Kamanabrou, J. Bonneterre, Philippe Saiag, J. Fra, V. Guillem Porta, A. Scherrer, Y. Menu, J. L.Gonzalez Larriba, Michael Weichenthal, Marie-Françoise Avril, Jean-Jacques Grob, T. Bieber, K. Neuber, J. Sufliarsky, Jean Jacques Bonerandi, Hubert Pehamberger, K. Gilde, Peter Mohr, Steinar Aamdal, Axel Hauschild
Publikováno v:
Journal of Clinical Oncology. 22:1118-1125
Purpose To compare fotemustine and dacarbazine (DTIC) in terms of overall response rate (ORR) as primary end-point and overall survival, duration of responses, time to progression, time to occurrence of brain metastases (BM), and to assess safety and
Autor:
Ulrike Leiter, Katharina C. Kähler, Marcus Both, Axel Hauschild, Gamze Senel, Dragana Lekic, Dirk Schadendorf, Michael Weichenthal, Peter Mohr, Ilka Senkpiehl, Selma Ugurel
Publikováno v:
Journal of Clinical Oncology. 35:9565-9565
9565 Background: Clinical cancer registration is increasingly important for healthcare delivery and outcome research in oncology. As compared to clinical trial data, information from clinical routine is often limited regarding the granularity and qua
Autor:
Christian U. Blank, Michael Millward, Peter Mohr, Marcus O. Butler, Christian Caglevic, Jose Lutzky, Steven J. O'Day, Nageatte Ibrahim, Igor Puzanov, Adil Daud, Erika Richtig, Kenneth Emancipator, Kim Margolin, Scot Ebbinghaus, Marta Nyakas, Ahmad A. Tarhini, Caroline Robert, Elaine McWhirter, Georgina V. Long, Honghong Zhou
Publikováno v:
Journal of Clinical Oncology. 34:9513-9513
9513Background: In KEYNOTE-006 (NCT01866319), pembro (MK-3475) provided superior OS and PFS and a lower grade 3-5 treatment-related AE rate over ipi in patients (pts) with advanced melanoma and ≤ 1 prior therapy. We assessed the impact of PD-L1 exp